https://www.pharmaceutical-technology.com/data-insights/azemiglitazone-cirius-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/
Azemiglitazone is under clinical development by Cirius Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
metabolic dysfunctionazemiglitazoneciriustherapeuticsassociated